Advertisement

Hematopoietic Growth Factors: Supportive and Priming Effects in AML

  • T. Büchner
  • W. Hiddemann
  • M. Zühlsdorf
  • B. Wörmann
  • J. Aswald
  • S. Aswald
  • G. Maschmeyer
  • W.-D. Ludwig
  • M.-C. Sauerland
  • A. Heinecke for the AMLCG
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 39)

Abstract

Growth factors have been administered after chemotherapy in 12 studies. Eight studies showed benefits in neutropenia and seven studies benefits in infections or survival or remissions. Clinical benefits are mainly found in high-risk patients. There are five negative studies according to major benefits, all five studies using E. coli produced GM-CSF. Growth factors before or together with chemotherapy were given in nine studies with trends to more remissions in one and to longer disease-free survival in three studies. Extending the priming strategy to more chemotherapy courses than having been done so far may further improve the antileukemic effect.

Keywords

Acute Myeloid Leukemia Acute Myelogenous Leukemia Cytosine Arabinoside Hematopoietic Growth Factor Acute Myeloid Leukemia Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ohno R, Tomonaga M, Kobayashi T et al. (1990) Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N Engl J Med 323: 871–877PubMedCrossRefGoogle Scholar
  2. 2.
    Dombret H, Chastang C, Fenaux, et al. (1995) A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. N Engl J Med 22: 1678–1683CrossRefGoogle Scholar
  3. 3.
    Heil G, Hoelzer D, Sanz MA et al. (1995) Results of a randomized double-blind placebo controlled phase III study of filgrastim in remission induction and early consolidation therapy for adults with de-novo acute myeloid leukemia. Blood 86 (suppl 1): 267aGoogle Scholar
  4. 4.
    Link H, Wandt H, Schönrock-Nabulsi P et al. (1996) G-CSF (Lenograstim) after chemotherapy for acute myeloid leukemia: A placebo controlled trial. Blood 88 (suppl 1): 666aGoogle Scholar
  5. 5.
    Büchner Th, Hiddemann, W, Koenigsmann M et al. (1991) Recombinant human granulocytemacrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse. Blood 78: 1190–1197PubMedGoogle Scholar
  6. 6.
    Rowe, JM, Andersen J, Mazza JJ et al. (1995) A randomized placebo-controlled phase III study of granulocyte-macrophage colony stimulating factor (GM-CSF) in adult patients (> 55–70 years) with acute myelogenous leukemia (AML). A study of the Eastern Cooperative Oncology Group (E1490). Blood 86: 457–462PubMedGoogle Scholar
  7. 7.
    Ohno R, Miyawaki S, Hatake K et al. (1995) Macrophage colony stimulating factor (M-CSF) reduces the incidence and duration of febrile neutropenia and shortens the period required to finish three courses of intensive consolidation therapy in acute myeloid leukemia (AML): A double-blind controlled study. Blood 86 (suppl 1): 266aGoogle Scholar
  8. 8.
    Estey EH, Dixon D, Kantarjian HM et al. (1990) Treatment of poor-prognostic newly diagnosed acute myeloid leukemia with Ara-C and recombinant human granulocyte-macrophage colony stimulating factor. Blood 75: 1766–1769PubMedGoogle Scholar
  9. 9.
    Witz F, Harousseau JL, Sadoun D et al. (1997) GM-CSF during and after remission induction treatment for elderly patients with acute myeloid leukemia (AML). Hematol Blood Transfus 40: 852–856Google Scholar
  10. 10.
    Stone RM, Berg DT, George SL et al. (1995) Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. N Engl J Med 332: 1671–1677PubMedCrossRefGoogle Scholar
  11. 11.
    Löwenberg B, Suciu S, Zittoun R et al. (1995) GM-CSF during as well as after induction chemotherapy (CT) in elderly patients with acute myeloid leukemia (AML). The EORTC/HOVON phase III trial (AML 11). Blood 86 (suppl 1): 433aGoogle Scholar
  12. 12.
    Zittoun R, Suciu S, Mandelli F et al. (1996) Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: A randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. J Clin Oncol 14: 2150–2159PubMedGoogle Scholar
  13. 13.
    Griffin JD, Young D, Hermann F et al. (1986) Effects of recombinant human GM-CSF on proliferation of clonogenic cells in acute myeloblastic leukemia. Blood 67: 1448–1453PubMedGoogle Scholar
  14. 14.
    Reuter C, Auf der Landwehr U, Schleyer E et al. (1994) Modulation of intracellular metabolism of cytosine arabinoside in acute myeloid leukemia by granulocyte-macrophage colony-stimulating factor. Leukemia 8: 217–225PubMedGoogle Scholar
  15. 15.
    Zühlsdorf M, Busemann C, Weißpfennig S et al. (1994) Priming with rhGM-CSF or rh-IL-3 for AML progenitors versus CFU-GM in vivo and in vitro: Significant increase in therapeutic ratio for cytosine arabinoside. Proc AACR 85: 211Google Scholar
  16. 16.
    Van Der Lely N, De Witte T, Wessels J et al. (1994) In vitro response of blasts to IL-3, GM-CSF, and G-CSF is different for individual AML patients: factors that stimulate leukemic clonogenic cells also enhance Ara-C cytotoxicity. Ann Hematol 68: 225–232PubMedCrossRefGoogle Scholar
  17. 17.
    Koistinen P, Wang C, Curtis JE et al. (1991) Granulocyte-macrophage colony-stimulating factor and interleukin-3 protect leukemic blast cells from Ara-C toxicity. Leukemia 5: 789–795PubMedGoogle Scholar
  18. 18.
    Lotem J, Sachs L (1992) Hematopoietic cytokines inhibit apoptosis induced by transforming growth factor bl and cancer chemotherapy compounds in myeloid leukemic cells. Blood 80: 1750–1778PubMedGoogle Scholar
  19. 19.
    Estey E, Hall PT, Kantarjian H et al. (1992) Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose Ara-C + daunorubicin: comparison to patients treated without GM-CSF. Blood 79: 2246–2255PubMedGoogle Scholar
  20. 20.
    Heil G, Chadid L, Hoelzer D et al. (1995) GMCSF in a double-blind randomized, placebo controlled trial on therapy of adult patients with de novo acute myeloid Leukemia (AML). Leukemia 9: 3–9PubMedGoogle Scholar
  21. 21.
    Büchner Th, Hiddemann W, Wörmann B et al. (1996) Age and karyotype-dependent effect of GM-CSF multiple course priming in AML. Blood 88 (suppl 1): 214aGoogle Scholar
  22. 22.
    Baer M.R., Bernstein SH, Brunetto VL et al. (1993) In vivo recombinant human G-CSF priming in previously untreated acute myeloid leukemia. Blood 26 Suppl 1: 328aGoogle Scholar
  23. 23.
    Estey E, Thall P, Andreeff M et al. (1994) Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: Comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol 12: 671–678PubMedGoogle Scholar
  24. 24.
    Ohno R, Naoe T, Kanamaru A et al. (1994) A double-blind study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Blood 83: 2086–2092PubMedGoogle Scholar
  25. 25.
    Bettelheim P, Valent P, Andreeff M et al. (1991) Recombinant human granulocyte-macrophage colony-stimulating factor in de novo acute myeloid leukemia. Blood 77: 700–711PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • T. Büchner
    • 1
  • W. Hiddemann
    • 1
  • M. Zühlsdorf
    • 1
  • B. Wörmann
    • 1
  • J. Aswald
    • 1
  • S. Aswald
    • 1
  • G. Maschmeyer
    • 1
  • W.-D. Ludwig
    • 1
  • M.-C. Sauerland
    • 1
  • A. Heinecke for the AMLCG
    • 1
  1. 1.Department of Hematology/OncologyUniversity of MünsterGermany

Personalised recommendations